LuMind Foundation-supported research has led to clinical trials currently in progress to address developmental cognitive deficits and those impairments associated with Alzheimer’s disease.
Roche, a leader in innovative research-focused healthcare and the world’s largest biotech company, has initiated a new multi-national Phase II clinical trial to evaluate the efficacy and safety of RG1662 in adolescents and adults, ages 12-30 years old, with Down syndrome. Following the successful completion of the previous groundbreaking Phase I clinical trial with this new drug that is being developed to address the cognitive and behavioral deficits in individuals with Down syndrome, this new significantly larger Phase II trial is a randomized, double-blind, placebo-controlled clinical study in which participants will be randomized to receive RG1662 either at low or high dose or placebo orally twice daily for 26 weeks.
This new trial, “A Study of RG1662 in Adults and Adolescents with Down Syndrome (CLEMATIS)”, will be conducted at multiple sites across the US, including La Jolla, CA, Sacramento, CA, Decatur, GA, Chicago, IL, Baltimore, MD, Boston, MA, Durham, NC, Dallas, TX, Salt Lake City, UT, and Madison, WI. In addition, the trial will be conducted at multiple international sites, including UK (4), France (4), Spain (3), Singapore (1), New Zealand (3), Canada (1), Mexico (5) and Argentina (2).
Visit our research section to learn more about the Phase II Roche clinical trial and other clinical trials.